Closed ATM View - NBA RFT 01/2019
Request for Tender – Supply of Imported Plasma and Recombinant Blood Products.
Show close time for other time zones
Canberra, Sydney, Melbourne, Adelaide, Perth, Brisbane, Darwin, Hobart
The aim of this procurement is to establish new supply arrangements for SHL and EHL rFVIII and rFIX products.
Successful tenderers will be required to supply rFVIII or rFIX products to meet orders from health providers in Australia, maintain contractually required supply security reserves, and provide a range of product support services.
The release of this Request for Tender follows consultation with clinical stakeholders and potential suppliers in January 2017. Key points identified from the consultation process and other market intelligence are as follows:
•In general, there is continued support for access to a secure supply of the safest and most efficacious therapies with a preference for EHL products.
•Administration kits and support material are not supplied for some products.
•The importance of patient access to products with administration devices suitable to all patients with different degrees of dexterity.
•A number of potential new product variants including SHL and EHL products, bypassing therapies to treat patients with inhibitors, monoclonal antibodies and gene therapy.
Submissions must be in the form prescribed in the attached Request for Tender. Failure to submit all of the required documentation by an Applicant may result in their offer being excluded from further consideration.
There are no specified minimum conditions for participation for this Request For Tender.
The term for the agreement shall be for a period of 3 years (initial term) with options to extend for two additional periods of 12 months, each at the NBA’s discretion. Supply arrangements will be operational from 1 January 2020. Suppliers may be required to support transition arrangements from the date of contract execution.